The radiotherapy device market size is projected to be worth US$ 6,805.43 million in 2023. The market is likely to reach US$ 12,895.19 million by 2033. The market is further expected to surge at a CAGR of 6.6% during the forecast period 2023 to 2033.
Attributes | Key Insights |
---|---|
Radiotherapy Device Market Estimated Size in 2023 | US$ 6,805.43 million |
Projected Market Value in 2033 | US$ 12,895.19 million |
Value-based CAGR from 2023 to 2033 | 6.6% |
Key Market Trends and Highlights
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The scope for radiotherapy device rose at a 7.9% CAGR between 2017 and 2022. The global market for radiotherapy device is anticipated to grow at a moderate CAGR of 6.6% over the forecast period 2023 to 2033.
The radiotherapy device market witnessed significant growth from 2018 to 2022, primarily driven by a rising global cancer incidence, AI and machine learning integration, expanding adoption of proton therapy, an increasing emphasis on sustainability and green practices, the exploration of emerging markets, and continuous technological innovations.
This period showcased remarkable developments and laid the foundation for future trends. Tailoring radiotherapy to individual patient needs and genetic profiles will dominate the landscape, making treatments more precise and effective. Combining radiotherapy with immunotherapy to bolster the patient immune response against cancer will continue to evolve. Further imaging and dose control innovations will ensure minimal damage to healthy tissues and maximum cancer cell destruction. Remote monitoring and teletherapy will become integral, ensuring broader accessibility to care.
The industry will continue to explore untapped potential in emerging markets, bringing advanced radiotherapy device to a broader global population. These projections indicate a need for transformative growth fueled by personalized approaches, innovative technology, and expanding global reach, solidifying its role in the fight against cancer.
The below table showcases revenues in terms of the top five leading countries, spearheaded by the United States. Besides the United States, some important growth countries include Germany, the United Kingdom, China, and India.
Forecast CAGRs from 2023 to 2033
United Kingdom | 5.2% |
---|---|
China | 7.6% |
India | 6.0% |
The United States is expected to account for 43% of the radiotherapy device sales in 2023. Growing emphasis on value based care models incentivizes healthcare providers to adopt radiotherapy device that can offer better outcomes and lower costs, promoting advanced technologies.
Integrating telemedicine and remote monitoring into radiotherapy services is becoming a game changer. This enhances patient accessibility and allows for more efficient, patient centric care. Evolving reimbursement structures and payment models encourage healthcare facilities to invest in modern radiotherapy device, aligning financial incentives with quality and value.
The proliferation of radiation oncology centers is expanding access to radiotherapy, especially in rural areas, addressing the issue of treatment accessibility. Utilizing advanced data analytics and machine learning for treatment planning and monitoring is revolutionizing the field, offering more precise and personalized treatments.
Germany is investing in proton and heavy ion therapy facilities, creating opportunities for advanced radiotherapy device to support precise cancer treatment with minimal side effects. A share of 6.8% is expected for the market in Germany in 2023.
The shift towards remote monitoring and teletherapy, accelerated by the COVID 19 pandemic, presents an avenue for innovative radiotherapy device solutions, ensuring accessibility and convenience for patients. Integrating artificial intelligence for treatment planning and personalized care offers immense potential for improved accuracy and efficiency in radiotherapy.
Collaborations between healthcare institutions and medical device manufacturers foster research and development, driving innovation in radiotherapy device technology. The growing focus on environmentally sustainable healthcare practices is promoting eco friendly radiotherapy device and techniques, meeting evolving market demands.
The United Kingdom is expected to register a 5.2% CAGR from 2023 to 2033. The United Kingdom is embracing innovative linear accelerator technology to offer more precise and efficient radiation therapy, minimizing side effects and enhancing patient outcomes.
The integration of machine learning for personalized treatment planning is improving the accuracy and efficiency of radiotherapy, optimizing dose distribution for each patient. Real time adaptive techniques allow treatment adjustments during sessions, accommodating changes in a patient anatomy and increasing treatment precision.
Innovative imaging technologies and robotic assistance are becoming integral in guiding radiotherapy procedures, offering real time monitoring and precise delivery. Telemedicine and remote consultations are gaining traction, ensuring accessible and convenient cancer care, especially for patients in remote areas.
From 2023 to 2033, China is expected to experience a 7.6% CAGR. Significant investment in proton therapy centers presents a lucrative opportunity for radiotherapy device manufacturers in China.
The region is expected to cater to a burgeoning demand for precise and minimally invasive cancer treatment. Integrating telemedicine and remote monitoring facilitates access to radiotherapy services in remote and underserved areas, providing a vast untapped market.
The adoption of artificial intelligence for personalized treatment plans in China is poised to enhance treatment accuracy and efficiency, promising to offer innovative solutions to patients.
Collaborations between domestic healthcare institutions and international medical device companies open up opportunities for research and development, fostering innovation in radiotherapy technology. China expanding middle class population seeks access to high quality healthcare, creating a substantial consumer base for advanced radiotherapy device and innovative cancer care solutions.
Radiotherapy device sales in India are expected to rise at a 6% CAGR until 2033. Brachytherapy is gaining momentum, offering targeted radiation therapy, particularly for prostate and cervical cancers, with improved precision and fewer side effects. India is witnessing increased interest in particle therapy, particularly proton therapy, due to its high accuracy and minimal damage to surrounding tissues, fostering opportunities for advanced device.
The expansion of radiotherapy services in rural areas is becoming a prominent trend, aligning with the government focus on accessible healthcare creating opportunities for innovative device. Telemedicine is being integrated to enhance accessibility and reach for radiotherapy services, addressing the challenges of remote patient care. Collaborations between Indian healthcare institutions and international partners drive significant research and development activities, spurring the development of innovative radiotherapy device.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Category | Market Share |
---|---|
External Beam Radiation Therapy Device | 78% |
Hospitals | 43% |
External beam radiation therapy devices are preferred in radiotherapy due to their versatility and precision. These devices offer non-invasive, targeted radiation delivery, minimizing damage to surrounding healthy tissues. A share of 78% is expected in 2023.
They effectively treat various cancer types and stages, making them a versatile choice for healthcare providers. Their advanced imaging and planning software allows for personalized treatment plans, ensuring the highest level of accuracy.
The no-contact nature of external beam radiation therapy enhances patient safety and comfort, promoting treatment adherence. This preference is driven by the ability of the device to offer precise, minimally invasive, and patient-centric care.
Hospitals are the preferred end users in the radiotherapy device market due to their comprehensive infrastructure and expertise. They offer a one stop cancer care solution, with specialized oncology departments and multidisciplinary teams. About 43% of radiotherapy device demand will be generated by hospitals in 2023.
Hospitals can invest in advanced radiotherapy device, ensuring precise and personalized treatment for various cancer cases. They can provide emergency and follow up care, making them the optimal patient choice. Hospitals also can handle the high initial setup and maintenance costs of radiotherapy equipment, ensuring consistent access to innovative treatments for cancer patients.
The competitive landscape in the radiotherapy device market is dynamic and multifaceted. A mix of established global players and innovative startups characterizes it. Leading companies such as Varian Medical Systems, Elekta, and Accuray continue to dominate, driving technological advancements and expanding their global presence.
They face competition from emerging players, particularly in Asia, focusing on cost effective solutions. The market is witnessing partnerships and collaborations between healthcare institutions and technology firms, fostering research and development. The key to success lies in embracing innovative technologies, staying compliant with stringent regulations, and ensuring a strong focus on patient centric care.
Product Portfolio
Attribute | Details |
---|---|
Estimated Market Size in 2023 | US$ 6,805.43 million |
Projected Market Valuation in 2033 | US$ 12,895.19 million |
Value-based CAGR 2023 to 2033 | 6.6% |
Forecast Period | 2023 to 2033 |
Historical Data Available for | 2018 to 2022 |
Market Analysis | Value in US$ million |
Key Regions Covered |
|
Key Market Segments Covered |
|
Key Countries Profiled |
|
Key Companies Profiled |
|
The radiotherapy device market is expected to reach US$ 6805.43 million in 2023.
The market for radiotherapy device is set to expand by a CAGR of 6.6% by 2033.
The radiotherapy device industry is forecast to reach US$ 12,895.19 million by 2033.
United States is likely the top performing market, holding a market share of 31.9% in 2023.
According to FMI's projections, the hospital sector is anticipated to maintain a 43% market share in 2023.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Supply Chain Analysis 3.5.1. Supply Side Participants and their Roles 3.5.1.1. Producers 3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers) 3.5.1.3. Wholesalers and Distributors 3.5.2. Value Added and Value Created at Node in the Supply Chain 3.5.3. List of Raw Material Suppliers 3.5.4. List of Existing and Potential Buyer’s 3.6. Investment Feasibility Matrix 3.7. Value Chain Analysis 3.7.1. Profit Margin Analysis 3.7.2. Wholesalers and Distributors 3.7.3. Retailers 3.8. PESTLE and Porter’s Analysis 3.9. Regulatory Landscape 3.9.1. By Key Regions 3.9.2. By Key Countries 3.10. Regional Parent Market Outlook 3.11. Production and Consumption Statistics 3.12. Import and Export Statistics 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) & Volume (Units) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) & Volume (Units) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Product, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Product, 2023 to 2033 5.3.1. External Beam Radiation Therapy Device 5.3.1.1. Linear Accelerators Device 5.3.1.2. Proton Therapy Device 5.3.2. Internal Beam Radiation Therapy Device 5.3.2.1. Brachytherapy Device 5.3.3. Others 5.4. Y-o-Y Growth Trend Analysis By Product, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Product, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By End User, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By End User, 2023 to 2033 6.3.1. Hospitals 6.3.2. Ambulatory Surgical Centers 6.3.3. Oncological Treatment Centers 6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Region, 2018 to 2022 7.3. Current Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Region, 2023 to 2033 7.3.1. North America 7.3.2. Latin America 7.3.3. Western Europe 7.3.4. Eastern Europe 7.3.5. South Asia and Pacific 7.3.6. East Asia 7.3.7. Middle East and Africa 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 8.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 8.2.1. By Country 8.2.1.1. USA 8.2.1.2. Canada 8.2.2. By Product 8.2.3. By End User 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Product 8.3.3. By End User 8.4. Key Takeaways 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Product 9.2.3. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Product 9.3.3. By End User 9.4. Key Takeaways 10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. UK 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Western Europe 10.2.2. By Product 10.2.3. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Product 10.3.3. By End User 10.4. Key Takeaways 11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Poland 11.2.1.2. Russia 11.2.1.3. Czech Republic 11.2.1.4. Romania 11.2.1.5. Rest of Eastern Europe 11.2.2. By Product 11.2.3. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Product 11.3.3. By End User 11.4. Key Takeaways 12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Bangladesh 12.2.1.3. Australia 12.2.1.4. New Zealand 12.2.1.5. Rest of South Asia and Pacific 12.2.2. By Product 12.2.3. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Product 12.3.3. By End User 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Product 13.2.3. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Product 13.3.3. By End User 13.4. Key Takeaways 14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Product 14.2.3. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Product 14.3.3. By End User 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. USA 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2022 15.1.2.1. By Product 15.1.2.2. By End User 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2022 15.2.2.1. By Product 15.2.2.2. By End User 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2022 15.3.2.1. By Product 15.3.2.2. By End User 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2022 15.4.2.1. By Product 15.4.2.2. By End User 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2022 15.5.2.1. By Product 15.5.2.2. By End User 15.6. UK 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2022 15.6.2.1. By Product 15.6.2.2. By End User 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2022 15.7.2.1. By Product 15.7.2.2. By End User 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2022 15.8.2.1. By Product 15.8.2.2. By End User 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2022 15.9.2.1. By Product 15.9.2.2. By End User 15.10. Poland 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2022 15.10.2.1. By Product 15.10.2.2. By End User 15.11. Russia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2022 15.11.2.1. By Product 15.11.2.2. By End User 15.12. Czech Republic 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2022 15.12.2.1. By Product 15.12.2.2. By End User 15.13. Romania 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2022 15.13.2.1. By Product 15.13.2.2. By End User 15.14. India 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2022 15.14.2.1. By Product 15.14.2.2. By End User 15.15. Bangladesh 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2022 15.15.2.1. By Product 15.15.2.2. By End User 15.16. Australia 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2022 15.16.2.1. By Product 15.16.2.2. By End User 15.17. New Zealand 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2022 15.17.2.1. By Product 15.17.2.2. By End User 15.18. China 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2022 15.18.2.1. By Product 15.18.2.2. By End User 15.19. Japan 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2022 15.19.2.1. By Product 15.19.2.2. By End User 15.20. South Korea 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2022 15.20.2.1. By Product 15.20.2.2. By End User 15.21. GCC Countries 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2022 15.21.2.1. By Product 15.21.2.2. By End User 15.22. South Africa 15.22.1. Pricing Analysis 15.22.2. Market Share Analysis, 2022 15.22.2.1. By Product 15.22.2.2. By End User 15.23. Israel 15.23.1. Pricing Analysis 15.23.2. Market Share Analysis, 2022 15.23.2.1. By Product 15.23.2.2. By End User 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Product 16.3.3. By End User 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Varian Medical Systems, Inc. 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.1.5.2. Product Strategy 17.1.1.5.3. Channel Strategy 17.1.2. Koninklijke Philips N.V. 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.2.5.2. Product Strategy 17.1.2.5.3. Channel Strategy 17.1.3. Elekta 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.3.5.2. Product Strategy 17.1.3.5.3. Channel Strategy 17.1.4. Accuray Incorporated 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.4.5.2. Product Strategy 17.1.4.5.3. Channel Strategy 17.1.5. IBA 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.5.5.2. Product Strategy 17.1.5.5.3. Channel Strategy 17.1.6. Siemens AG 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.6.5.2. Product Strategy 17.1.6.5.3. Channel Strategy 17.1.7. Isoray Inc. 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.7.5.2. Product Strategy 17.1.7.5.3. Channel Strategy 17.1.8. BEBIG Medical GmbH 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.8.5.2. Product Strategy 17.1.8.5.3. Channel Strategy 17.1.9. RaySearch Laboratories 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.9.5.2. Product Strategy 17.1.9.5.3. Channel Strategy 17.1.10. Vision RT Ltd 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 17.1.10.5.2. Product Strategy 17.1.10.5.3. Channel Strategy 17.1.11. TOSHIBA CORPORATION 17.1.11.1. Overview 17.1.11.2. Product Portfolio 17.1.11.3. Profitability by Market Segments 17.1.11.4. Sales Footprint 17.1.11.5. Strategy Overview 17.1.11.5.1. Marketing Strategy 17.1.11.5.2. Product Strategy 17.1.11.5.3. Channel Strategy 17.1.12. Theragenics Corp 17.1.12.1. Overview 17.1.12.2. Product Portfolio 17.1.12.3. Profitability by Market Segments 17.1.12.4. Sales Footprint 17.1.12.5. Strategy Overview 17.1.12.5.1. Marketing Strategy 17.1.12.5.2. Product Strategy 17.1.12.5.3. Channel Strategy 17.1.13. Mitsubishi Electric Corporation 17.1.13.1. Overview 17.1.13.2. Product Portfolio 17.1.13.3. Profitability by Market Segments 17.1.13.4. Sales Footprint 17.1.13.5. Strategy Overview 17.1.13.5.1. Marketing Strategy 17.1.13.5.2. Product Strategy 17.1.13.5.3. Channel Strategy 17.1.14. AngioDynamics 17.1.14.1. Overview 17.1.14.2. Product Portfolio 17.1.14.3. Profitability by Market Segments 17.1.14.4. Sales Footprint 17.1.14.5. Strategy Overview 17.1.14.5.1. Marketing Strategy 17.1.14.5.2. Product Strategy 17.1.14.5.3. Channel Strategy 17.1.15. SHINVA MEDICAL INSTRUMENT CO., LTD. 17.1.15.1. Overview 17.1.15.2. Product Portfolio 17.1.15.3. Profitability by Market Segments 17.1.15.4. Sales Footprint 17.1.15.5. Strategy Overview 17.1.15.5.1. Marketing Strategy 17.1.15.5.2. Product Strategy 17.1.15.5.3. Channel Strategy 17.1.16. Neusoft Corporation. 17.1.16.1. Overview 17.1.16.2. Product Portfolio 17.1.16.3. Profitability by Market Segments 17.1.16.4. Sales Footprint 17.1.16.5. Strategy Overview 17.1.16.5.1. Marketing Strategy 17.1.16.5.2. Product Strategy 17.1.16.5.3. Channel Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Healthcare
February 2024
REP-GB-16820
342 pages
Explore Healthcare Insights
View Reports